What was the overall market valuation of the US agnosia treatment market in 2024?

The overall market valuation was $27.48 Million in 2024. Read More

What is the projected market valuation for the US agnosia treatment market by 2035?

The projected valuation for 2035 is $42.65 Million. Read More

What is the expected CAGR for the US agnosia treatment market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 4.08%. Read More

What were the segment valuations for diagnosis in the US agnosia treatment market?

The segment valuations for diagnosis included $8.24 Million for CT and $10.99 Million for MRI. Read More

What are the leading causes of agnosia and their market valuations?

Leading causes include Alzheimer's disease at $10.99 Million and Pick's disease at $6.74 Million. Read More

What types of agnosia are recognized in the market, and what are their valuations?

Types of agnosia include visual agnosia at $15.0 Million and auditory agnosia at $3.5 Million. Read More

What treatment options are available for agnosia, and what are their market valuations?

Treatment options include surgery at $5.0 Million and antibiotics for cerebral abscess at $10.0 Million. Read More

How does the market for visual agnosia compare to other types of agnosia?

Visual agnosia, valued at $15.0 Million, significantly outpaces other types such as auditory agnosia at $3.5 Million. Read More

What trends are anticipated in the US agnosia treatment market by 2035?

Trends suggest a growing market, with a projected increase to $42.65 Million by 2035, driven by advancements in treatment and diagnosis. Read More

US Agnosia Treatment Market

Q: Which companies are considered key players in the US agnosia treatment market?

Key players include Roche, Novartis, Pfizer, Johnson & Johnson, Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Merck & Co., and Sanofi. Read More

ID: MRFR/Pharma/18316-HCR 100 Pages Satyendra Maurya Last Updated: September 10, 2026

US Agnosia Treatment Market Research Report: Size, Share, Trend Analysis By Diagnosis (CT, MRI) - Growth & Industry Forecast 2025 To 2035

US Agnosia Treatment Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)4.08%

2024 Market Size$ 27.48 Million

2025 Market Size$ 28.6 Million

2035 Market Size$ 42.65 Million

Key Players

Roche

Novartis

Pfizer

Johnson & Johnson

Bristol-Myers Squibb

Eli Lilly and Company

Trends

Personalized Treatment Approaches
Integration of Technology
Telehealth Expansion

Opportunities

Increased Research Funding
Growing Awareness and Education
Advancements in Diagnostic Techniques

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Diagnosis (USD Million)
  1. 4.1.1 Computed Tomography (CT)
  2. 4.1.2 Magnetic Resonance Imaging (MRI)
  3. 4.1.3 Others
2. 4.2 Pharmaceutical, BY Causes (USD Million)
  1. 4.2.1 Alzheimer's disease
  2. 4.2.2 Pick's disease
  3. 4.2.3 MELAS
  4. 4.2.4 Balint's syndrome
3. 4.3 Pharmaceutical, BY Type (USD Million)
  1. 4.3.1 auditory agnosia
  2. 4.3.2 gustatory agnosia
  3. 4.3.3 olfactory agnosia
  4. 4.3.4 tactile agnosia
  5. 4.3.5 visual agnosia
  6. 4.3.6 others
4. 4.4 Pharmaceutical, BY Treatment (USD Million)
  1. 4.4.1 surgery
  2. 4.4.2 antibiotics for cerebral abscess
  3. 4.4.3 radiation of brain tumor
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Pfizer (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Johnson & Johnson (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Bristol-Myers Squibb (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Eli Lilly and Company (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merck & Co. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sanofi (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DIAGNOSIS
3. 6.3 US MARKET ANALYSIS BY CAUSES
4. 6.4 US MARKET ANALYSIS BY TYPE
5. 6.5 US MARKET ANALYSIS BY TREATMENT
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY DIAGNOSIS, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY CAUSES, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY CAUSES, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY TREATMENT, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY TREATMENT, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.2.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.2.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.2.4 BY TREATMENT, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Enquiry

Customize Report

US US Agnosia Treatment Market Segmentation

US Agnosia Treatment Market By Diagnosis (USD Million, 2025-2035)

Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Others

US Agnosia Treatment Market By Causes (USD Million, 2025-2035)

Alzheimer's disease
Pick's disease
MELAS
Balint's syndrome

US Agnosia Treatment Market By Type (USD Million, 2025-2035)

auditory agnosia
gustatory agnosia
olfactory agnosia
tactile agnosia
visual agnosia
others

US Agnosia Treatment Market By Treatment (USD Million, 2025-2035)

surgery
antibiotics for cerebral abscess
radiation of brain tumor

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”